Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages

  Ngeow, Joanne ^a   He, Xin ^a   Mester, Jessica L ^a,b   Lei, Junying ^a   Romigh, Todd ^a   Orloff, Mohammed S ^a,b   Milas, Mira ^a,b   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN HYDROLYSATE;

ADULT; ARTICLE; CONTROLLED STUDY; COWDEN SYNDROME; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ANALYSIS; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPLICING DEFECT; THYROID CANCER; WILD TYPE;

ADENOMA; ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEINS; PTEN PHOSPHOHYDROLASE; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84870742906     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2944     Document Type: Article

References (42)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin KA 2012 SEER data submission SEER Cancer Statistics Review, 1975-2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute
2. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C 2011 Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 96:E2063-E2071
3. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C 2012 Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407
4. Zbuk KM, Eng C 2007 Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7:35-45 (Pubitemid 46020845)
5. Eng C 2000 Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37:828-830
6. Pilarski R, Eng C 2004 Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 41:323-326 (Pubitemid 38608513)
7. Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN 2010 Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8:562-594
8. Mester JL, Zhou M, Prescott N, Eng C 2012 Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology 79:1187.e1-1187.e7
9. Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, Eriksson AW 1986 The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 29:222-233 (Pubitemid 16136974)
10. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713 (Pubitemid 27468972)
11. Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, Porter K, Eng C, Ringel MD, Kloos RT 2011 Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid 21:505-510
12. Marsh DJ, Zheng Z, Zedenius J, Kremer H, Padberg GW, Larsson C, Longy M, Eng C 1997 Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res 57:500-503 (Pubitemid 27082319)
13. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C 2000 Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700 (Pubitemid 30646707)
14. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C 1999 PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8:185-193 (Pubitemid 29054260)
15. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C 1999 Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260 (Pubitemid 29488932)
16. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboué B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, et al. 1998 Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7:507-515 (Pubitemid 28120643)
17. Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C 2011 A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 88:42-56
18. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, Dunn T, Feit H, Geraghty MT, Graham Jr JM, Hodgson SV, Hunter A, Korf BR, Manchester D, Miesfeldt S, Murday VA, Nathanson KL, Parisi M, Pober B, Romano C, Eng C, et al. 1999 PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.Hum Mol Genet 8:1461-1472 (Pubitemid 29374079)
19. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP 2010 Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42:454-458
20. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 67:959-966
21. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP 2001 Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27:222-224 (Pubitemid 32157454)
22. Eng C, Thiele H, Zhou XP, Gorlin RJ, Hennekam RC, Winter RM 2001 PTEN mutations and proteus syndrome. Lancet 358:2079-2080
23. van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A, Macek M, Matthijs G, Bakker E 2009 Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well Light Scanner. Hum Mutat 30:899-909
24. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G 2002 Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
25. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C 2007 Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet 81:756-767 (Pubitemid 47596543)
26. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, Matloff E, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C 2003 Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 73:404-411 (Pubitemid 36921003)
27. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsäter H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C 2007 Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 144B:484-491 (Pubitemid 46983159)
28. Hornik K 2012 The R FAQ. http://cran.r-project.org/doc/FAQ/R-FAQ.html
29. Dahia PM, Gimm O, Chi H, Marsh DJ, Reynolds PR, Eng C 2000 Absence of germline mutations in MINPP1, a phosphatase encoding gene centromeric of PTEN, in patients with Cowden and Bannayan-Riley-Ruvalcaba syndrome without germline PTEN mutations. J Med Genet 37:715-717
30. Marsh DJ, Dahia PL, Coulon V, Zheng Z, Dorion-Bonnet F, Call KM, Little R, Lin AY, Eeles RA, Goldstein AM, Hodgson SV, Richardson AL, Robinson BG, Weber HC, Longy M, Eng C 1998 Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 21:61-69 (Pubitemid 28028108)
31. Yan H, Dobbie Z, Gruber SB, Markowitz S, Romans K, Giardiello FM, Kinzler KW, Vogelstein B 2002 Small changes in expression affect predisposition to tumorigenesis. Nat Genet 30:25-26
32. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C 2000 Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60:3147-3151 (Pubitemid 30407908)
33. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H 1999 The tumor-suppressor activity of PTEN is regulated by its carboxylterminal region. Proc Natl Acad Sci USA 96:10182-10187 (Pubitemid 29422533)
34. Salmena L, Carracedo A, Pandolfi PP 2008 Tenets of PTEN tumor suppression. Cell 133:403-414 (Pubitemid 351622014)
35. Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C 2002 Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 11:445-450 (Pubitemid 34213618)
36. Planchon SM, Waite KA, Eng C 2008 The nuclear affairs of PTEN. J Cell Sci 121:249-253 (Pubitemid 351356695)
37. Jacob AI, Romigh T, Waite KA, Eng C 2009 Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Res 19:203-210
38. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T 2007 MicroRNA-21 regulates expression of the PTEN tumor suppressor gene inhumanhepatocellular cancer. Gastroenterology 133:647-658 (Pubitemid 47187346)
39. Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K, Liu MF, Li Y 2011 Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA 108:10144-10149
40. Di Loreto C, Tell G, Pestrin M, Pandolfi M, Damante G, Puglisi F 2005 PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 224:105-109 (Pubitemid 40720371)
41. Gimm O, Attié-Bitach T, Lees JA, Vekemans M, Eng C 2000 Expression of the PTEN tumour suppressor protein during human development. Hum Mol Genet 9:1633-1639 (Pubitemid 30427000)
42. Barletta JA, Bellizzi AM, Hornick JL 2011 Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome. Am J Surg Pathol 35:1505-1511